sur CROSSJECT (EPA:ALCJ)
CROSSJECT Expands Leadership for New Industrial and Commercial Phase
CROSSJECT has announced a strategic expansion of its Executive Board, now comprising five members: Olivier Lacombe, Didier Morin, Lionel Seltz, Patrick Alexandre, and Isabelle Liebschutz. This restructuring aims to strengthen the company's governance as it moves towards the industrialization and distribution of its innovative ZENEO® needle-free auto-injector technology.
The company's focus is shifting from securing FDA registration for its ZEPIZURE® product to scaling industrial operations and building its U.S. commercial presence. The expanded board represents key areas including pharmaceutical development, industrial operations, and financial management, reflecting CROSSJECT's commitment to effective execution during this critical phase.
Additionally, CROSSJECT US has enhanced its regulatory leadership by appointing David Pudwill as Vice President, Regulatory & Scientific Affairs, reinforcing its efforts in the American market.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CROSSJECT